This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.
Left ventricular ejection fraction (LVEF) of > 40% within 12 months prior to screening.
Structural heart disease evidence.
HF diagnosed with New York Heart Association (NYHA) Class II-IV at the time of screening.
BMI <25 kg/m² at screening.
History of type 1 diabetes.
HbA1c ≥10% at screening.
Currently receiving or anticipated to receive therapeutic intervention for diabetic retinopathy and/or macular edema.